Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I study of RO5503781 in advanced malignancies
NL-OMON37762Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of idasanutlin in advanced cancer, Nonhematologic neoplasms and lymphoma (2 arms), sponsored by Roche. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicities and 1 more. Started Feb 2012; status: active, not recruiting.
02
Drugs
idasanutlin
03
Conditions
advanced cancerNonhematologic neoplasmslymphoma
Beyond the preview
Go deeper on NL-OMON37762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37762.